Morphic Holding, Inc. (NASDAQ:MORF) CEO Praveen P. Tipirneni sold 6,099 shares of the firm’s stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $30.09, for a total value of $183,518.91. Following the completion of the sale, the chief executive officer now directly owns 6,199 shares in the company, valued at $186,527.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Praveen P. Tipirneni also recently made the following trade(s):

  • On Tuesday, November 3rd, Praveen P. Tipirneni sold 2,605 shares of Morphic stock. The shares were sold at an average price of $25.99, for a total value of $67,703.95.

Shares of Morphic stock opened at $29.51 on Friday. The business’s fifty day simple moving average is $27.36 and its 200 day simple moving average is $24.93. The firm has a market capitalization of $918.50 million, a P/E ratio of -14.54 and a beta of 0.96. Morphic Holding, Inc. has a 12 month low of $9.90 and a 12 month high of $31.07.

Morphic (NASDAQ:MORF) last issued its earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.60. The firm had revenue of $25.76 million during the quarter, compared to the consensus estimate of $7.70 million. On average, research analysts anticipate that Morphic Holding, Inc. will post -1.72 EPS for the current fiscal year.

Several equities analysts have commented on the company. Zacks Investment Research upgraded Morphic from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Tuesday, November 17th. Royal Bank of Canada initiated coverage on Morphic in a report on Monday, October 26th. They issued an “outperform” rating and a $35.00 target price for the company. ValuEngine cut Morphic from a “buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $37.00 price objective on shares of Morphic in a research note on Wednesday, August 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Morphic currently has an average rating of “Buy” and an average target price of $35.00.

Several institutional investors and hedge funds have recently modified their holdings of MORF. Wells Fargo & Company MN raised its stake in shares of Morphic by 88.5% in the first quarter. Wells Fargo & Company MN now owns 8,184 shares of the company’s stock valued at $120,000 after buying an additional 3,843 shares during the period. State Street Corp raised its stake in shares of Morphic by 133.0% in the first quarter. State Street Corp now owns 169,158 shares of the company’s stock valued at $2,483,000 after buying an additional 96,548 shares during the period. SG Americas Securities LLC bought a new stake in shares of Morphic in the second quarter valued at $201,000. New York State Common Retirement Fund raised its stake in shares of Morphic by 112.3% in the second quarter. New York State Common Retirement Fund now owns 12,102 shares of the company’s stock valued at $327,000 after buying an additional 6,402 shares during the period. Finally, California Public Employees Retirement System bought a new stake in shares of Morphic in the second quarter valued at $819,000. Hedge funds and other institutional investors own 60.84% of the company’s stock.

Morphic Company Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avÃ6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4Ã7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD).

Further Reading: Hedge Funds – Risk or Reward?

Insider Buying and Selling by Quarter for Morphic (NASDAQ:MORF)

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.